Controversies in Drug Allergy: Radiographic Contrast Media: Special Article
Controversies in Drug Allergy: Radiographic Contrast Media: Special Article
Controversies in Drug Allergy: Radiographic Contrast Media: Special Article
This article is one of a series of international consensus documents developed from the International Drug Allergy Symposium held at
the Joint Congress of the American Academy of Allergy, Asthma & Immunology/World Allergy Organization on March 1, 2018, in
Orlando, Florida, USA. The symposium was sponsored by The Journal of Allergy and Clinical Immunology, The Journal of Allergy
and Clinical Immunology: In Practice, and The World Allergy Organization Journal and chaired by Mariana Castells, MD, PhD, and
Pascal Demoly, MD, PhD.
The risk for developing immediate or delayed hypersensitivity Key words: Anaphylaxis; Drug allergy; Premedication; Radio-
reactions to radiocontrast media (RCM) interferes with the graphic contrast media; RCM; Skin testing
diagnosis and treatment of a number of patients requiring imaging
diagnostic methods for many common diseases. A group of experts Worldwide more than 75 million X-ray examinations are
met in Orlando, Florida, in March 2018 to analyze the similarities performed per year using radiographic contrast media (RCM).
and differences in the management of RCM reactions in different RCMs are categorized based on ion content (Table I), and
areas of the world. This paper presents a summary of the currently nonionic RCMs are preferred more in clinical practice
recommendations provided by this consensus group, highlighting owing to their lower hypersensitivity profile.1-4
controversial issues and unmet needs that require further The prevalence of hypersensitivity reactions to monomeric ionic
research. Ó 2019 American Academy of Allergy, Asthma & RCM has been reported to vary between 3.8% and 12.7%, and
Immunology (J Allergy Clin Immunol Pract 2019;7:60-4) severe reactions occur in 0.02% to 0.04% of intravenous applica-
tions.5 For nonionic RCM, the observed prevalence is 0.7% to 3%.6
Two types of hypersensitivity reactions to RCM have been
recognized: immediate and nonimmediate (delayed).7 Immediate
a
Allergy and Clinical Immunology Department, Centro Médico Docente La Trinidad reactions can be caused by IgE and non-IgE mechanisms. Im-
b
and Clínica El Avila, Caracas, Venezuela mediate, anaphylaxis-like reactions may be caused by an effect of
Department of Dermatology and Venerology, Medical University of Graz, Graz, the RCM on the mast cell membrane leading to mediator release
Austria
c
Department of Dermatology and Allergy Biederstein, Technische Universität
or, possibly, by direct complement activation. IgE-mediated
München, Munich, Germany allergic hypersensitivity reactions may have been underreported
d
Department of Chest Diseases, Division of Immunology and Allergy, Ankara in the past,1-4,8-13 due to the lack of allergy testing.
University School of Medicine, Ankara, Turkey Macular or maculopapular exanthema seems to account for
e
Department of Allergy and Clinical Immunology, Medical University, H. S. Joao,
Porto, Portugal
the great majority of RCM-induced nonimmediate reactions.
f
Department of Medicine, Division of Allergy and Immunology, Northwestern Although the mechanisms of these exanthematous reactions have
University Feinberg School of Medicine, Chicago, Ill not been fully elucidated, T-cell involvement has been suggested
g
Department of Medicine, Service of Allergy and Clinical Immunology, Centre in delayed hypersensitivity to RCMs (Figure 1).14 Previous
Hospitalier de l’Université de Montréal, Montréal, Quebec, Canada reactions to RCM are the main risk factor for developing
h
Laboratory of Clinical Immunology, Department of Microbiology and Clinical
Immunology, KU Leuven, Leuven, Belgium
hypersensitivity reactions to RCM. Other factors that have been
i
Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, associated with an increased risk to develop hypersensitivity
Germany reactions to RCM are atopy and asthma (Table II).
* These authors were topic co-leaders.
No funding was received for this work.
Conflicts of interest: P. A. Greenberger has received consultancy fees from Allergy CONTROVERSIAL AREAS
Therapeutics; receives royalties from Up To Date and Wolters Kluwer Lippincott,
The role of the basophil activation test
Williams and Wilkins; and has provided expert witness testimony. The rest of the
authors declare that they have no relevant conflicts of interest. The usefulness of the basophil activation test (BAT) to study
Received for publication June 27, 2018; accepted for publication June 27, 2018. reactions to RCM has been investigated in some centers, but still
Corresponding author: Mario Sánchez-Borges, MD, Clínica El Avila, 6a. transversal remains a research tool and needs further validation.2 For RCM,
Urb. Altamira, piso 8, consultorio 803, Caracas 1060, Venezuela. E-mail: BAT sensitivity varies from 46% to 62%, and although speci-
[email protected].
2213-2198
ficity is high (88% to 100%), the results do not correlate with
Ó 2019 American Academy of Allergy, Asthma & Immunology symptom severity. Further research is required before routine
https://doi.org/10.1016/j.jaip.2018.06.030 usage of this diagnostic method can be recommended.12,15
60
J ALLERGY CLIN IMMUNOL PRACT SÁNCHEZ-BORGES ET AL 61
VOLUME 7, NUMBER 1
Ionic monomers with high osmolality Sodium iothalamate 54% 325 1843
Meglumin diatrizoate 65% 306 1530
Ionic dimers with low osmolality Meglumin ioxaglate 39.5% 320 580
Sodium ioxaglate 19.6% 320 580
Nonionic monomers Iopamidol 61.2% 300 616
Iohexol 64.6% 300 640
Ioversol 63.6% 300 645
Iopromid 62.3% 300 610
Nonionic dimers Iotrolan 64.1% 300 320
Iodixanol 65.2% 300 290
Non
IgE-mediated
immunologic TABLE III. Skin test concentrations recommended for iodinated
radiocontrast media*
Readings
Direct effects of RCM Nonimmediate
the RCM Test concentration Immediate reactions reactions†
13 Corticosteroid: prednisone 50 mg PO
RCM 7 Corticosteroid: prednisone 50 mg PO
RCM
known 1 Corticosteroid: prednisone 50 mg PO
unknown
1 Anti-H1 antihistamine: 1 mg/kg PO or IM
+ - diphenhydramine
IM, Intramuscular route; PO, oral administration.
Skin test with a ID test Skin prick and ID tests *Modified from Greenberger and Patterson.28
panel of RCM dil 1:10 with a panel
If posive: +
avoid this one - patients to assess the impact (efficacy/safety) of different pre-
If negave: medication protocols on clinical outcomes are needed.
Consider DPT
consider DPT
or Hypersensive Non
or
premedicaon rechallenge hypersensive REFERENCES
or alternave 1. Kim MH, Lee SY, Lee SE, Yang MS, Jung JW, Park CM, et al. Anaphylaxis to
RCM iodinated contrast media: clinical characteristics related with development of
anaphylactic shock. PLoS One 2014;9:e100154.
2. Salas M, Gomez F, Fernandez TD, Doña I, Aranda A, Ariza A, et al. Diagnosis
FIGURE 2. Skin testebased management of patients with im- of immediate hypersensitivity reactions to radiocontrast media. Allergy 2013;
mediate reactions to radiocontrast media. DPT, Drug provocation 68:1203-6.
test; RCM, radiocontrast media. 3. Goksel O, Aydın O, Atasoy C, Akyar S, Demirel YS, Misirligil Z, et al. Hy-
persensitivity reactions to contrast media: prevalence, risk factors and the role of
skin tests in diagnosis—a cross-sectional survey. Int Arch Allergy Immunol
Posive history of 2011;155:297-305.
4. Brockow K, Ring J. Anaphylaxis to radiographic contrast media. Curr Opin
Nonimmediate reacon
Allergy Clin Immunol 2011;11:326-31.
5. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K.
Adverse reactions to ionic and nonionic contrast media. A report from the
Patch and intradermal tests
Japanese Committee on the Safety of Contrast Media. Radiology 1990;175:
with reading at 48 and 72 hours 621-8.
6. Li X, Liu H, Zhao L, Liu J, Cai L, Liu L, et al. Clinical observation of adverse
+ - drug reactions to non-ionic iodinated contrast media in population with un-
derlying diseases and risk factors. Br J Radiol 2017;90:20160729.
7. Brockow K. Immediate and delayed reactions to radiocontrast media: is there an
Rechallenge
Rechallenge with allergic mechanism? Immunol Allergy Clin North Am 2009;29:453-68.
with alternave, 8. Laroche D, Namour F, Lefrançois C, Aimone-Gastin I, Romano A, Sainte-
culprit RCM
skin test Laudy J, et al. Anaphylactoid and anaphylactic reactions to iodinated contrast
negave RCM material. Allergy 1999;54(suppl 58):13-6.
9. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an
indicator of mast-cell activation in systemic anaphylaxis and mastocytosis.
N Engl J Med 1987;316:1622-6.
Rechallenge
Not 10. Laroche D, Aimone-Gastin I, Dubois F, Huet H, Gérard P, Vergnaud MC, et al.
with alternave, Mechanisms of severe, immediate reactions to iodinated contrast material.
hypersensive
skin test Radiology 1998;209:183-90.
negave RCM 11. Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A, Bonadonna P, et al.
Skin testing in patients with hypersensitivity reactions to iodinated contrast
media—a European multicenter study. Allergy 2009;64:234-41.
RCM are contraindicated in paents with Stevens Johnson 12. Pinnobphun P, Buranapraditkun S, Kampitak T, Hirankarn N,
Syndrome, Toxic epidermal necrolysis or DRESS. Klaewsongkram J. The diagnostic value of basophil activation test in patients
with an immediate hypersensitivity reaction to radiocontrast media. Ann Allergy
Asthma Immunol 2011;106:387-93.
FIGURE 3. Skin testebased management of patients with non- 13. Mita H, Tadokoro K, Akiyama K. Detection of IgE antibody to a radiocontrast
medium. Allergy 1998;53:1133-40.
immediate reactions to radiocontrast media (RCM). RCM are 14. Kanny G, Pichler W, Morisset M, Franck P, Marie B, Kohler C, et al. T cell-
contraindicated in patients with Stevens-Johnson syndrome, toxic mediated reactions to iodinated contrast media: evaluation by skin and
epidermal necrolysis, or DRESS. DRESS, Drug reaction with lymphocyte activation tests. J Allergy Clin Immunol 2005;115:179-85.
eosinophilia and systemic symptoms. 15. Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-
Cernadas J, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/
EAACI Drug Allergy Interest Group position paper. Allergy 2016;71:1103-34.
patient’s care. Prospective investigations are needed that help 16. Rosado Ingelmo A, Doña Diaz I, Cabañas Moreno R, Moya Quesada MC,
clarify the clinical usefulness of skin testing with RCM to García-Avilés C, García Nuñez I, et al. Clinical practice guidelines for diagnosis
confirm or exclude an RCM allergy diagnosis and to select and management of hypersensitivity reactions to contrast media. J Investig
alternative RCMs in patients with a history of reactions. Beyond Allergol Clin Immunol 2016;26:144-53.
17. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A,
tryptase, good diagnostic tools to evaluate the mechanism of Bilo MB, et al. Skin test concentrations for systemically administered drugs—an
RCM hypersensitivity reactions in real time are needed. Finally, ENDA/EAACI Drug Allergy Interest Group position paper. Allergy 2013;68:
controlled prospective multicentric studies with large numbers of 702-12.
64 SÁNCHEZ-BORGES ET AL J ALLERGY CLIN IMMUNOL PRACT
JANUARY 2019
18. Brockow K, Sánchez-Borges M. Hypersensitivity to contrast media and dyes. 30. Lasser EC, Berry CC, Mishkin MM, Williamson B, Zheutlin N, Silverman JM.
Immunol Allergy Clin North Am 2014;34:547-64. Pretreatment with corticosteroids to prevent adverse reactions to nonionic
19. Gall H, Pillekamp H, Peter RU. Late-type allergy to the X-ray contrast medium contrast media. AJR Am J Roentgenol 1994;162:523-6.
Solutrast (iopamidol). Contact Dermatitis 1999;40:248-50. 31. Tramer MR, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of
20. Caimmi S, Benyahia B, Suau D, Bousquet-Rouanet L, Caimmi D, Bousquet PJ, serious anaphylactic reactions due to iodinated contrast media: systematic re-
et al. Clinical value of negative skin tests to iodinated contrast media. Clin Exp view. BMJ 2006;333:675-81.
Allergy 2010;40:805-10. 32. Trcka J, Schmidt C, Seitz CS, Bröcker E-B, Gross GE, Trautmann A.
21. Kvedariene V, Martins P, Rouanet L, Demoly P. Diagnosis of iodinated contrast Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-
media hypersensitivity: results of a 6-year period. Clin Exp Allergy 2006;36: mediated allergy? AJR Am J Roentgenol 2008;190:666-70.
1072-7. 33. Dawson P, Sidhu PS. Is there a role for corticosteroid prophylaxis in patients at
22. Torres MJ, Gomez F, Doña I, Rosado A, Mayorga C, Garcia I, et al. Diagnostic increased risk of adverse reactions to intravascular contrast agents? Clin Radiol
evaluation of patients with nonimmediate cutaneous hypersensitivity reactions 1993;48:225-6.
to iodinated contrast media. Allergy 2012;67:929-35. 34. Bartlett MJ, Bynevelt M. Acute contrast reaction management by radiologists: a
23. Joint Task Force on Practice Parameters; American Academy of Allergy, local audit study. Australas Radiol 2003;47:363-7.
Asthma and Immunology; American College of Allergy, Asthma and 35. O’Neill JM, McBride KD. Cardiopulmonary resuscitation and contrast media
Immunology; Joint Council of Allergy, Asthma and Immunology. Drug al- reactions in a radiology department. Clin Radiol 2001;56:321-5.
lergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 36. Yoon SH, Lee SY, Kang HR, Kim JY, Hahn S, Park CM, et al. Skin tests in
105:259-73. patients with hypersensitivity reaction to iodinated contrast media: a meta-
24. ACR Manual on Contrast Media. Version 10.3. ACR Committee on Drugs and analysis. Allergy 2015;70:625-37.
Contrast Media. American College of Radiology; 2017. 37. Ansell G, Tweedie MC, West CR, Evans P, Couch L. The current status of
25. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, reactions to intravenous contrast media. Invest Radiol 1980;15(suppl):S32-9.
et al. International consensus on drug allergy. Allergy 2014;69:420-37. 38. Lang DM, Alpern MB, Visintainer PF, Smith ST. Elevated risk of
26. Schrijvers R, Breynaert C, Ahmedali Y, Bourrain JL, Demoly P, Chiriac A. Skin anaphylactoid reaction from radiographic contrast media is associated with
testing for suspected iodinated contrast media hypersensitivity. J Allergy Clin both beta-blocker exposure and cardiovascular disorders. Arch Intern Med
Immunol Pract 2018;6:1246-54. 1993;153:2033-40.
27. Lerondeau B, Trechot P, Waton J, Poreaux C, Luc A, Schmutz JL, et al. 39. Pradubpongsa P, Dhana N, Jongjarearnprasert K, Janpanich S, Thongngarm T.
Analysis of cross-reactivity among radiocontrast media in 97 hypersensitivity Adverse reactions to iodinated contrast media: prevalence, risk factors and
reactions. J Allergy Clin Immunol 2016;137:833-5. outcome—the results of a 3-year period. Asian Pac J Allergy Immunol 2013;31:
28. Greenberger PA, Patterson R. The prevention of immediate generalized re- 299-306.
actions to radiocontrast media in high-risk patients. J Allergy Clin Immunol 40. Cochrane ST. Anaphylactoid reactions to radiocontrast media. Curr Allergy
1991;87:867-72. Asthma Rep 2005;5:28-31.
29. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short 41. Bonadonna P, Pagani M, Aberer W, Bilò MB, Brockow K, Oude Elberink H,
term use of oral corticosteroids and related harms among adults in the United et al. Drug hypersensitivity in clonal mast cell disorders: ENDA/EAACI posi-
States: population based cohort study. BMJ 2017;357:j1415. tion paper. Allergy 2015;70:755-63.